Three-year data highlights inflammation control in psoriatic arthritis
News
Argenx presents new efgartigimod data at EULAR 2025
Rheumatology studies show promising results for Sjogren’s disease
Tagomics secures £860k grant for colorectal cancer test
Biotech firm to collaborate with NHS on early detection study
PharmaTimes Clinical Researcher of the Year – The Americas
Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!
EC approves Santen’s Ryjunea to slow progression of paediatric myopia
Therapy indicated for children aged 3 to 14 at treatment initiation
Linear Diagnostics awarded £1m to develop rapid STI test
New funding supports development of diagnostic platform
NICE recommends Sogroya for growth hormone deficiency in children
Treatment provides option for children with growth failure
PharmaTimes Clinical Researcher of the Year – The Americas
Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!
NICE recommends mirikizumab for Crohn’s disease treatment
New guidance expands treatment options for eligible patients
AstraZeneca’s Forxiga recommended for chronic kidney disease treatment
Updated guidance from NICE expands eligibility for dapagliflozin us
Lumanity and Parker Institute partner to support delivery of new immunotherapies
The alliance combines Lumanity’s commercial and development strategy capabilities with PICI’s translational research expertise
TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share...
Eli Lilly acquires SiteOne Therapeutics to advance treatment for chronic pain
Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid...
NICE recommends sparsentan for IgA nephropathy
First non-immunosuppressive dual-action therapy approved for eligible patients
Oxford Brain Diagnostics to launch groundbreaking dementia diagnosis technology
Company secures regulatory approvals for commercial rollout in UK and US
